Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT04367506 |
Other study ID # |
1R34MH120142 |
Secondary ID |
|
Status |
Recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 1, 2021 |
Est. completion date |
June 2024 |
Study information
Verified date |
September 2023 |
Source |
University of Maryland, Baltimore |
Contact |
Melanie Bennett, Ph.D. |
Phone |
410-706-2490 |
Email |
mbennett[@]som.umaryland.edu |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
All patients with serious mental illness are abstinent while in the hospital for a
psychiatric admission yet almost all return to smoking after discharge. The investigators
propose to adapt a digital intervention both to the needs of SMI smokers and to being
introduced in the inpatient psychiatric setting through a collaboration between experts in
SMI and the Truth Initiative, a pre-eminent tobacco control organization. The investigators
believe this will bridge the inpatient to outpatient gap in cessation services and will help
people remain abstinent following hospital discharge.
Description:
Persons with serious mental illness (SMI) die on average 10-15 years earlier than those in
the general population. Smoking is the strongest risk factor for their elevated mortality.
Helping SMI smokers to quit is an urgent and unmet need. The hospital is an optimal setting
to provide smoking cessation services. Hospital admissions for SMI are common with more than
1.2 million inpatient stays for schizophrenia and mood disorders per year in the US.
Hospitalized patients experience required abstinence, are available for counseling, and can
try cessation medications in a supportive setting. The challenge is how to engage SMI
patients in cessation services post-discharge. An easy-to-access digital intervention is a
scalable and sustainable way to bridge the inpatient-to-outpatient gap and to promote
sustained abstinence. Digital interventions can deliver all elements of cessation treatment
and yield quit rates comparable to face to face and telephonic interventions. SMI patients
use and benefit from technology-based interventions but currently there is no digital smoking
cessation program addressing their needs. This R34 application will adapt a proven digital
intervention, BecomeAnEX (EX), developed and run by Truth Initiative for over 10 years. Its
core components are real-time one on one coaching via live chat, nicotine replacement therapy
decision support and delivery, personalized quit plans, a large online social network for
peer support, a robust and fully integrated text message program, and tailored email
messaging. Adaptation will ensure that EX addresses the specific challenges of SMI smokers
and is in line with principles of mental health recovery. In Aim 1 the investigators will
develop and obtain preliminary feedback about EX-SMI, a version of EX adapted for SMI
patients. A priori target mechanisms are motivation, abstinence self-efficacy, and cravings.
In Aim 2 the investigators will conduct a one-arm pilot trial and obtain feedback from 20 SMI
smokers recruited during psychiatric hospitalization and followed up at 2-weeks and 1-month
post-discharge. Feasibility and acceptability will be assessed via participant feedback
regarding their intervention experience, changes in motivation, self-efficacy and cravings,
and automated tracking data on EX-SMI use post-discharge. In Aim 3, 90 SMI smokers recruited
during psychiatric hospitalization will be randomized to usual care or to a revised version
of EX-SMI and followed for 3 months after the hospital stay. The investigators will compare
the feasibility/acceptability of EX-SMI, measure intervention impact on target mechanisms,
and obtain initial estimates of efficacy on 7-day point prevalence abstinence. This pilot
work directly addresses priorities of this RFA in refining and optimizing an efficacious
intervention for a new target population. Ultimately, this program of research could have a
powerful public health impact by increasing smoking cessation among persons with SMI.